

The future of the Bayesian Biostatistics in the regulatory world

James Travis

Currently most Bayesian designs are considered complex and are typically challenging to design and review but with clear advantages and gains compared to traditional designs. How do we ensure these types of designs to become more commonplace?

In this presentation I will discuss the steps necessary to accomplish this goal, namely setting clearer expectations, establishing a common vocabulary and a need for clearer communication.

Disclaimer: This speech reflects the views of the author and should not be construed to represent FDA's views or policies.